291 Results
Sort By:
Published on October 31, 2024
Using spatial genomics technology, studies in preclinical animal models, and evaluation of tumor specimens from ovarian cancer (OvCa) patients, scientists at the Icahn School of Medicine at Mount Sinai discovered ovarian cancer tumors produce interleukin-4 (IL-4)—which is typically associated with asthma and the skin condition eczema—to produce a protective tumor…
Published on October 1, 2024
The international ovarian tumor analysis (IOTA) ADNEX ultrasound test detected 96% of ovarian cancers in postmenopausal women and should become standard of care in the U.K., according to researchers who just published a new study comparing methods. “This is the first time that a head-to-head study of all available ovarian…
Published on September 18, 2024
Researchers from the Wellcome Sanger Institute and their collaborators investigated RAD51C and uncovered over 3,000 harmful genetic changes that could potentially disrupt its function and increase cancer risk in breast and ovarian cancer. The findings are published in the journal Cell and paves the way for better risk assessment and…
Published on July 18, 2024
A new study conducted by researchers at the Huntsman Cancer Institute at the University of Utah, the Spencer Fox Eccles School of Medicine at the University of Utah, and Boston University Chobanian & Avedisian School of Medicine has found that women with severe endometriosis are 10 times more likely to…
Published on June 27, 2024
Moffitt Cancer Center investigators, reporting in the journal Cell Systems, report the development of a new adaptive therapy approach to ovarian cancer poly-adenosine ribose polymerase (PARP) inhibitor treatments that promises a more personalized and less toxic treatment option for patients. Toxicity and emerging drug resistance are challenges in providing PARP…
Published on February 14, 2024
A nanopore-based urine test for ovarian cancer may be able to diagnose the disease much earlier, according to new research from Joseph Reiner and colleagues at Virginia Commonwealth University. The team has determined multiple peptide signatures that might herald the disease. Reiner presented their research at the 68th Biophysical Society…
Published on January 26, 2024
A major bottleneck in early detection is the molecular heterogeneity between ovarian cancer (OC) patients, which limits the likelihood of identifying individual biomarkers that are shared among patients. In a new study “A personalized probabilistic approach to ovarian cancer diagnostics,” published in Gynecologic Oncology, researchers from Georgia Institute of Technology…
Published on December 7, 2023
A test that measures overall genomic instability in routine cervical smears can detect aggressive ovarian cancer up to nine years before its clinical diagnosis, research suggests. Whole-genome sequencing of DNA purified from Pap smears, which are routinely collected during cervical cancer screening, highlighted women who had gone on to develop…
Published on December 1, 2023
AbbVie continues the ADC party and beefs up its anti-solid tumor portfolio with the acquisition of ImmunoGen for $10.1B. ImmuoGen’s flagship cancer therapy is Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), according to an announcement yesterday. This has been the year of the…
Published on September 22, 2023
A small clinical trial conducted by investigators at Ludwig Cancer Research has shown that a treatment regimen for advanced ovarian cancer patients by combining adoptive T cell therapy (ACT) with a personalized cancer vaccine doubled overall survival time in patients. The research, detailed Thursday in Nature Cancer, was led by…
Published on August 16, 2023
A team of investigators at City of Hope, one of the largest cancer research and treatment organizations in the US, report in Nature Communications that they have engineered a CAR T cell therapy for advanced ovarian cancer that has shown promise in laboratory and preclinical models. Based on the preclinical…
Published on August 9, 2023
A new study describes a new diagnostic approach that could help identify the 15% of women with ovarian cancer whose tumors are intrinsically refractory to standard platinum-based therapies, the most common type of chemotherapy for the disease. Most ovarian cancers are very sensitive to platinum therapy, at least initially. However,…
Published on July 12, 2023
New findings from researchers at Nagoya University in Japan have revealed new potential biomarkers for ovarian cancer found in extracellular vesicles (EVs). The three previously unknown membrane proteins in extracellular vesicles (EVs) derived from high-grade serous ovarian carcinoma (HGSOC), a deadly subtype of epithelial ovarian cancer (EOC). The group used…
Published on May 24, 2023
Researchers led by a team from the University of Helsinki in Finland have identified three different evolutionary states in tumors from patients with ovarian high-grade serous carcinoma (HGSC) that are characterized by distinct signaling pathways and associated with treatment response. HGSC is the most common epithelial ovarian cancer subtype and…
Published on April 18, 2023
As part of the annual meeting of the American Association for Cancer Research (AACR) in Orlando, FL, researchers from the Perelman School of Medicine at the University of Pennsylvania have not only identified a new target for drug-resistant ovarian cancer but also provided supporting evidence for a potential treatment approach.…